UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

British journal of haematology, 2015-05, Vol.169 (3), p.423-434

2015

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk‐1: A Potential Therapeutic Strategy for Myeloma Bone Disease

Journal of bone and mineral research, 2016-06, Vol.31 (6), p.1225-1234

2016

Link zum Volltext

Verfügbarkeit prüfen

TRACP‐5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia

JBMR plus, 2022-11, Vol.6 (11), p.e10690-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

Bone (New York, N.Y.), 2013-04, Vol.53 (2), p.487-496

2013

Link zum Volltext

Verfügbarkeit prüfen

Role of Decorin in Multiple Myeloma (MM) Bone Marrow Microenvironment

Journal of bone and mineral research, 2015-03, Vol.30 (3), p.465-470

2015

Link zum Volltext

Verfügbarkeit prüfen

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2489-2500

2014

Link zum Volltext

Verfügbarkeit prüfen

FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cells

Biochemical and biophysical research communications, 2008-02, Vol.366 (2), p.471-475

2008

Link zum Volltext

Verfügbarkeit prüfen

The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells

European journal of haematology, 2010-07, Vol.85 (1), p.68-75

2010

Link zum Volltext

Verfügbarkeit prüfen

Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy

The Journal of clinical investigation, 2016-04, Vol.126 (4), p.1300-1310

2016

Link zum Volltext

Verfügbarkeit prüfen

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

Leukemia, 2013-12, Vol.27 (12), p.2366-2375

2013

Link zum Volltext

Verfügbarkeit prüfen

Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.(phosphorylated signal transducer and activator of transcription 3)

The Journal of clinical investigation, 2016-04, Vol.126 (4)

2016

Link zum Volltext

Verfügbarkeit prüfen

Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts

Blood, 2015-12, Vol.126 (23), p.4200-4200

2015

Link zum Volltext

Verfügbarkeit prüfen

Bone Disease in Multiple Myeloma

Cancer treatment and research, 2016, Vol.169, p.251-270

2016

Link zum Volltext

Verfügbarkeit prüfen

Role Of Decorin In Multiple Myeloma (MM) Bone Marrow Microenvironment

Blood, 2013-11, Vol.122 (21), p.1851-1851

2013

Link zum Volltext

Verfügbarkeit prüfen

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Blood, 2015-12, Vol.126 (23), p.2992-2992

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.4255-4255

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.5726-5726

2014

Link zum Volltext

Verfügbarkeit prüfen

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.4431-4431

2013

Link zum Volltext

Verfügbarkeit prüfen

Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulation

International journal of oncology, 2011-11, Vol.39 (5), p.1327-1336

2011

Link zum Volltext

Verfügbarkeit prüfen

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.1822-1822

2012

Link zum Volltext

Verfügbarkeit prüfen

Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma

Blood, 2012-11, Vol.120 (21), p.3990-3990

2012

Link zum Volltext

Verfügbarkeit prüfen

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Blood, 2012-11, Vol.120 (21), p.3989-3989

2012

Link zum Volltext

Verfügbarkeit prüfen

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Blood, 2012-11, Vol.120 (21), p.1871-1871

2012

Link zum Volltext

Verfügbarkeit prüfen

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Blood, 2011-11, Vol.118 (21), p.1819-1819

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk‐1: A Potential Therapeutic Strategy for Myeloma Bone Disease

TRACP‐5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

Role of Decorin in Multiple Myeloma (MM) Bone Marrow Microenvironment

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cells

The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.(phosphorylated signal transducer and activator of transcription 3)

Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts

Bone Disease in Multiple Myeloma

Role Of Decorin In Multiple Myeloma (MM) Bone Marrow Microenvironment

The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulation

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Suchergebnisse filtern